✦ LIBER ✦

Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment

✍ Scribed by R.M. Kagan; P.K. Cheung; T.K. Huard; M.A. Lewinski

Book ID: 113457290
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 454 KB
Volume: 71
Category: Article
ISSN: 0166-3542
DOI: 10.1016/j.antiviral.2006.02.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term follow-up of 11 protease inhib

Long-term follow-up of 11 protease inhibitor (PI)-naïve and PI-treated HIV-infected patients harbouring virus with insertions in the HIV-1 protease gene

✍ C Amiel; C Charpentier; N Désiré; P Bonnard; M-G Lebrette; L Weiss; G Pialoux; V 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 292 KB

The cumulative occurrence of resistance

The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients

✍ Marina Karmochkine; Ali Si Mohamed; Christophe Piketty; Christine Ginsburg; Gill 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 120 KB

Drug resistance mutations and newly reco

Drug resistance mutations and newly recognized treatment-related substitutions in the HIV-1 protease gene: Prevalence and associations with drug exposure and real or virtual phenotypic resistance to protease inhibitors in two clinical cohorts of antiretroviral experienced patients

✍ Carlo Torti; Eugenia Quiros-Roldan; Laura Monno; Andrea Patroni; Annalisa Saraci 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

## Abstract This study aimed at identifying HIV‐1 protease amino acid changes associated with protease inhibitor (PI) exposure and susceptibility. New amino acid substitutions were correlated with the number of experienced PIs, reaching statistical significance only for those at positions 3, 44, an

Switching children previously exposed to

Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial

✍ Louise Kuhn; Ashraf Coovadia; Renate Strehlau; Leigh Martens; Chih-Chi Hu; Tammy 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 249 KB

Efficacy and safety of once daily elvite

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

✍ Jean-Michel Molina; Anthony LaMarca; Jaime Andrade-Villanueva; Bonaventura Clote 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 209 KB